Answers are grounded in this paper and cite their sources.
Reveals immune characteristics in the brain of an infant with AT/RT, suggesting potential for immunotherapy.
Atypical Teratoid/Rhabdoid Tumors (AT/RT) are rare brain tumors with high mortality. The overall immune characteristics of these tumors remain understudied. This knowledge gap is due to the rare rate of occurrence, limited information of immune microenvironment in brains of infants prior to treatment, and most available tissues being from heavily-treated individuals. We obtained autopsy brain tissue and blood within 12-hours of death from an 8-week-old infant with untreated AT/RT and performed high-parameter flow cytometry. We successfully isolated immune cells from autopsy brain and blood (PBMC: 92% viable, brain: 54.4% viable cells). Unlike brain tissue isolated from newly-diagnosed adult glioblastoma, this 8-week-old AT/RT patient brain had infiltration of activated PD1+ CD8 T-cells. While significant numbers of CD8 T-cells with high expression of proliferation marker (Ki67) and activation markers (PD1, CD69) were found in the brain, no evidence of exhaustion was seen (low-to-no expression of Tim3, Lag3, CTLA4). Few T-regs and suppressive myeloid cells were observed inside the brain. In the matched blood, few T-cells were found, which likely reflects infant lymphopenia. To determine the immune landscape of healthy infant brains, we used 4-day-old mice. We found various immune cells in brains of healthy four-day-old mice which is an age developmentally similar to 8-week-old humans. Similar to the human brain with AT/RT, we found evidence of T-cell proliferation in brains of healthy mice on day 4 post-birth indicating a potential role for immune cells in the developing brain. In the context of AT/RT, immune phenotype is likely conducive to immunotherapies due to few T-regs and suppressive myeloid cells, lack of T-cell exhaustion, and significant numbers of PD1+ CD8 T cells in the brain. Understanding the state of immunity in brains of infants and children will pave the way for design of appropriate immunotherapies that may be effective as fist lines of therapy.
No takes yet. Share an insight, caveat, or question.
Ayasoufi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: